Press

Red Light Holland Sells ~350,000 Grams of Magic Truffles and Increases Points of Sale for iMicrodose Packs

Jul 14 • 3 min read

Quick Take: Red Light Holland has sold approx. 350,000 grams of packaged Magic Truffles and now has iMicrodose Packs for sale in 30 Smart Shops, including brick and mortar stores. Red Light Holland Corp. (CSE: TRIP), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the…

Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Jul 9 • 2 min read

Quick Take: Cybin Inc. has announced their plans for operational expansion to Europe. These plans include moving its intellectual portfolio to its wholly-owned Ireland-based subsidiary. Cybin Inc. (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical research organizations,…

Horizons ETFs Rebalances World’s First Psychedelics ETF

Jul 7 • 1 min read

Quick Take: Horizon ETFs, has rebalanced their psychedelic-focused ETF (NEO: PSYK) Horizons ETFs Management (Canada) Inc. has completed the quarterly rebalance of the constituent holdings of Horizons Psychedelic Stock Index ETF (NEO: PSYK). PSYK is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in, or significant…

Braxia Scientific Announces Participation at PSYCH Investor Summit on July 7, 2021

Jul 6 • 2 min read

Quick Take: Braxia Scientific will be participating at the PSYCH Investor Summit on July 7 Braxia Scientific Corp. (CSE: BRAX), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will…

Seelos Therapeutics Doses First Patient in a Study of Intranasal Ketamine for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Jul 6 • 4 min read

Quick Take: Seelos Theraputics has dosed the first patient in the second part of their registrational study. The double-blind placebo-controlled study is focused on adult patients with major depression disorder at imminent risk of suicide. Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441